Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.53 |
| ▸ | PPARA | Q07869 | 8/20 | 0.53 |
| ▸ | PPARD | Q03181 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096637 | 0.89 | PPARG (0.56) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL18580379 | 0.86 | PPARG (0.56) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096924 | 0.86 | PPARG (0.51) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL12096674 | 0.85 | PPARG (0.52) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL14057067 | 0.84 | PPARG (0.39) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL12096746 | 0.83 | PPARG (0.48) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL2218298 | 0.83 | PPARG (0.80) | PPARGPPARAPPARDRORC | |
| SCHEMBL14053616 | 0.83 | TP53 (0.42) | PPARGPPARAPPARDALDH1A1L3MBTL1 | |
| SCHEMBL1444435 | 0.83 | PPARG (0.48) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096858 | 0.83 | PPARG (0.46) | PPARGPPARAPPARDALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | PPARG 423/4885PPARA 564/4885PPARD 302/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | PPARG 324/4885PPARA 227/4885PPARD 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.